Healthtech funding in 2014
European Healthtech startup funding raised during 2014.
In 2014, 123 European Healthtech companies closed 134 funding rounds and raised €928M in equity funding (excluding debt and grants). Debt rounds added €649k. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 6 Nov 2026.
Equity funding
€928M
excl. debt & grants · +€649k debt
Funding rounds
134
Companies
123
Top country
UK
Healthtech: last three years
change vs the year before| Year | Equity | Change | Rounds | Change | Debt |
|---|---|---|---|---|---|
| 2012 | €480M | -9.1% | 74 | +12.1% | — |
| 2013 | €631M | +31.5% | 121 | +63.5% | €914k |
| 2014 | €928M | +47.1% | 134 | +10.7% | €649k |
Rank among sectors
#5
7.2% of sector funding
Debt financing
€649k
0.1% of total
Top-10 round share
49.5%
of disclosed capital
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, 2014 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €64M | 12 |
| Feb | €70M | 7 |
| Mar | €23M | 11 |
| Apr | €151M | 17 |
| May | €66M | 11 |
| Jun | €14M | 12 |
| Jul | €18M | 7 |
| Aug | €58M | 9 |
| Sep | €170M | 12 |
| Oct | €40M | 9 |
| Nov | €129M | 12 |
| Dec | €128M | 15 |
Top countries
by € raisedHealthtech — top countries by capital, 2014 — interactive chart.
Data table
| Healthtech — top countries by capital, 2014 | |
|---|---|
| UK | €241M |
| Switzerland | €233M |
| Israel | €89M |
| Sweden | €86M |
| France | €84M |
| Denmark | €51M |
| Netherlands | €43M |
| Germany | €38M |
Stage mix
by € raisedHealthtech — stage mix, 2014 — interactive chart.
Data table
| Healthtech — stage mix, 2014 | |
|---|---|
| Series B | €201M |
| Series D+ | €196M |
| Series A | €172M |
| Other | €159M |
| Series C | €65M |
| Growth/Late | €61M |
| Early VC | €43M |
| Seed | €32M |
| Grant | €3.2M |
| Debt | €649k |
Largest equity rounds
by disclosed amount, 2014| Company | Stage | Date | Amount |
|---|---|---|---|
| Adaptimmune | Series A | Sep 2014 | €79M |
| Biocartis | Series D+ | Sep 2014 | €65M |
| Cell Medica | Series B | Nov 2014 | €64M |
| NovImmune | Series D+ | Feb 2014 | €49M |
| Ascendis Pharma | Series C | Dec 2014 | €48M |
| Wilson Therapeutics | Other | Apr 2014 | €36M |
| Quanta Fluid Solutions | Series B | Nov 2014 | €34M |
| uTest_Vamsi | Series D+ | Jan 2014 | €31M |
| Kymab | Series B | May 2014 | €29M |
| Xeltis | Series B | Dec 2014 | €27M |
Largest debt rounds
debt financing, 2014; not in the equity total| Company | Stage | Date | Amount |
|---|---|---|---|
| SelfDiagnostics | Debt | Feb 2014 | €649k |
Top investors
most active in 2014, by deal count- High-Tech Gründerfonds (HTGF)4 deals
- Imprimatur Capital3 deals
- Life Sciences Partners3 deals
- Wellington Partners3 deals
- Capricorn Partners2 deals
- Imperial Innovations Limited2 deals
- Index Ventures2 deals
- Kerala Ventures2 deals
- Lanzadera2 deals
- Seventure Partners2 deals
Source: Tech.eu Funding Explorer · data as of 6 Nov 2026 · licence CC BY 4.0 · Methodology